Spyre Therapeutics (SYRE) Change in Acquisitions & Divestments (2016 - 2026)

Spyre Therapeutics' Change in Acquisitions & Divestments history runs 11 years deep, the most recent figure standing at $107.7 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 50.94% year-over-year to $107.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.1 million (up 51.37% YoY) and the FY2025 annual result came in at $371.7 million, up 51.13% from the prior year.
• Change in Acquisitions & Divestments was $107.7 million for Q1 2026 at Spyre Therapeutics, up from $94.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $107.7 million in Q1 2026 and bottomed at $3.2 million in Q2 2023.
• A 5-year average of $53.9 million and a median of $52.8 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments sank 87.0% — and 2024, when it soared 1680.8%.
• Spyre Therapeutics' Change in Acquisitions & Divestments stood at $18.5 million in 2022, then increased by 2.16% to $18.9 million in 2023, then soared by 230.94% to $62.5 million in 2024, then soared by 50.76% to $94.3 million in 2025, then climbed by 14.26% to $107.7 million in 2026.
• Business Quant data shows SYRE's Change in Acquisitions & Divestments at $107.7 million in Q1 2026, $94.3 million in Q4 2025, and $99.2 million in Q3 2025.